The Pharmaceutical Benefits Scheme (PBS) subsidises ruxolitinib (Jakavi®) for patients with myelofibrosis.
Treatment with ruxolitinib (Jakavi®) is subsidised through the PBS under Section 85 of the National Health Act 1953.
This item is available for patients with primary myelofibrosis or post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis who are classified as:
- high risk or intermediate–2 risk, or
- intermediate–1 risk with severe disease related symptoms that are resistant, refractory or intolerant to available therapy
The Schedule of Pharmaceutical Benefits on the PBS website outlines restrictions for prescribing ruxolitinib (Jakavi®) to patients.
All initial applications must include a copy of the bone marrow biopsy report which confirms the diagnosis of myelofibrosis.
Classification of risk of myelofibrosis must be provided in accordance with either the:
- Myelofibrosis International Prognostic Scoring System (IPSS)or
- Dynamic International Prognostic Scoring System (DIPSS), or
- Age Adjusted DIPSS
Patients who have been treated with non PBS subsidised ruxolitinib (Jakavi®) before 1 February 2016 must submit details of the previous treatment. The details are to include:
- the date when treatment with ruxolitinib (Jakavi®) was initiated
- a bone marrow biopsy report which confirms the diagnosis of myelofibrosis,
- confirmation the PBS restriction criteria for the relevant risk category was met at the time of initiation, and
- the method by which ruxolitinib (Jakavi®) treatment was accessed at the time of initiation, such as through a compassionate use program
Schedule item details
Dose – ruxolitinib (Jakavi®) is available as:
- 5 mg tablets in a pack size of 56
- 15 mg tablets in a pack size of 56
- 20 mg tablets in a pack size of 56
The recommended starting dose of ruxolitinib (Jakavi®) is based on platelet count:
|Platelet Count||Starting Dose|
50 - 100 x 109/L
5 mg twice daily
100 - 200 x 109/L
15 mg twice daily
200 x 109/L
20 mg twice daily
No increase in the maximum quantity may be authorised for the 15 mg and 20 mg dose strengths.
Lodging an application
All initial application requests must:
- be made in writing
- include the Myelofibrosis Initial PBS authority application Supporting information form (PB172)
- include a copy of the bone marrow biopsy report confirming diagnosis of myelofibrosis, and
- Include a completed authority prescription form
Send all written applications to the Complex Drugs address on the contact us page.
Authority applications for continuing treatment may be made in writing or by calling the Complex Drugs enquiry line on the contact us page
For more information contact us on the Complex Drugs enquiry line.